Climb Bio Inc (CLYM) — Strategic Asset Allocation Index
Climb Bio Inc (CLYM) has a Strategic Asset Allocation Index of 24.8% as of March 2026. Strategic assets (PP&E of $- plus long-term investments of $36.74 Million) total $36.74 Million, measured against net assets of $148.09 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check CLYM cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
Climb Bio Inc Strategic Asset Allocation Index (2020–2025)
This chart shows how Climb Bio Inc's Strategic Asset Allocation Index has evolved across 6 annual periods from 2020 to 2025. As of March 2026, the index stands at 24.8%, representing strategic assets of $36.74 Million against net assets of $148.09 Million USD. See CLYM free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for Climb Bio Inc (2020–2025)
The table below presents the year-by-year Strategic Asset Allocation Index for Climb Bio Inc from 2020 to 2025, covering 6 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Climb Bio Inc stock valuation.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 37.1% | $59.57 Million | $- | $59.57 Million | $160.47 Million | ▲ +8.0 pp |
| 2024 | 29.1% | $61.61 Million | $- | $61.61 Million | $211.88 Million | ▲ +29.1 pp |
| 2023 | 0.0% | $0.00 | $- | $0.00 | $107.60 Million | ▲ +0.0 pp |
| 2022 | 0.0% | $0.00 | $- | $0.00 | $128.72 Million | ▼ -14.9 pp |
| 2021 | 14.9% | $24.92 Million | $- | $24.92 Million | $167.20 Million | ▲ +14.9 pp |
| 2020 | 0.0% | $0.00 | $- | $0.00 | $21.57 Million | — |